Novo Nordisk, the Danish pharmaceutical company, has surged past luxury goods giant LVMH to become the most valuable company in Europe. This remarkable feat is largely due to the skyrocketing demand for its weight-loss drugs, Wegovy and Ozempic, which have tremendously boosted Novo Nordisk's shares by 40% this year.
With a market capitalization of 2.96 trillion Danish krone ($428 billion), Novo Nordisk has overtaken LVMH, whose market value stands at around $416 billion. LVMH, known for its brands such as Louis Vuitton and Hennessy, has faced challenges due to China's slowing economy. As a result, its stock has dropped 8% over the past six months, despite a 12% gain this year.
The surge in Novo Nordisk's shares can largely be attributed to the success of Wegovy and Ozempic, both of which have witnessed a significant surge in sales in recent months. Ozempic, originally developed to treat type 2 diabetes and containing the same active ingredient as Wegovy, has been prescribed by some physicians to assist patients with weight loss.
Furthermore, Novo Nordisk made an announcement on Monday that Wegovy would be available in the UK through a controlled and limited launch. The UK's National Health Service has confirmed that Wegovy will be offered as an option for weight management, albeit limited to patients with at least one weight-related condition such as hypertension or cardiovascular disease. This move is expected to offer potential relief for thousands suffering from weight-related ailments.
Clinical trials have shown that Wegovy can help individuals lose 15% of their body weight in less than 16 months. Additionally, recently published results from a five-year trial demonstrated that Wegovy reduced the risk of heart attack, stroke, or heart-related death by 20%. However, despite its immense potential, Novo Nordisk is struggling to keep up with the surging demand for Wegovy. The drug is only available in a few countries outside the United States, and the company anticipates supply constraints in the foreseeable future.
Novo Nordisk's CEO, Lars Fruergaard Jørgensen, believes that the company has only begun to scratch the surface of the drug's potential impact. With over one billion people worldwide classified as obese, the demand for effective weight-loss solutions is immense. Consequently, Novo Nordisk is investing billions of dollars to increase production capacity and running its factories around the clock.
The company's financials reflect the success of its drugs, with profits of almost 49 billion Danish krone ($7 billion) in the first half of this year alone, a 30% increase compared to the same period in 2022. This surge in profits has also led to an influx of US dollars into Denmark's economy, causing the value of the Danish krone to rise. To address this, Denmark's central bank has kept interest rates lower than those set by the European Central Bank, dissuading foreign investments and reducing the currency's value.
Novo Nordisk is optimistic about continued growth and now expects its profits to rise by up to 37% this year, significantly higher than the 19% increase forecasted in February.
However, not all analysts are convinced that Novo Nordisk's success will translate into further gains in its stock price. UBS analysts have reiterated their recommendation to sell the shares, citing uncertainties regarding the willingness of healthcare providers to pay for Wegovy. Limited healthcare budgets and the complexity and cost of addressing obesity with pharmacology could potentially restrict patient access to the drug, impacting Novo Nordisk's future growth prospects.